We are live on ! Find out more
TGTX icon

TG Therapeutics
TGTX

132 hedge funds and large institutions have $534M invested in TG Therapeutics in 2018 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 50 increasing their positions, 36 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

141% more call options, than puts

Call options by funds: $20.8M | Put options by funds: $8.63M

44% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 16

39% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 36

6% more funds holding

Funds holding: 125 → 132 (+7)

1.11% more ownership

Funds ownership: 51.07% → 52.17% (+1.1%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

3% less capital invested

Capital invested by funds: $548M → $534M (-$13.9M)

Holders
132
Holders Change
+7
Holders Change %
+5.6%
% of All Funds
3.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
23
Increased
50
Reduced
36
Closed
16
Calls
$20.8M
Puts
$8.63M
Net Calls
+$12.2M
Net Calls Change
+$5.15M

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$24.8M
2
Wells Fargo
Wells Fargo
California
+$11.7M
3
BlackRock
BlackRock
New York
+$8.33M
4
State Street
State Street
Massachusetts
+$8.17M
5
OM
Opaleye Management
Massachusetts
+$4.82M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$16M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.57M
3
SAM
Senzar Asset Management
New York
-$6.11M
4
ACA
Avoro Capital Advisors
New York
-$3.85M
5
UBS AM
UBS AM
Illinois
-$3.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
HMS
126
Hanseatic Management Services
New Mexico
$1K – – –
SEI Investments
127
SEI Investments
Pennsylvania
$1K +$303 +22 +50%
PCM
128
Prelude Capital Management
New York
$1K +$1.07K +78 New
TWA
129
TCI Wealth Advisors
Arizona
$1K +$1.38K +100 New
Point72 Asset Management
130
Point72 Asset Management
Connecticut
– -$8.57M -603,800 Closed
Wellington Management Group
131
Wellington Management Group
Massachusetts
– -$1.51M -106,021 Closed
GC
132
Guggenheim Capital
Illinois
– -$1.06M -74,974 Closed
SIP
133
Stoneridge Investment Partners
Pennsylvania
– -$798K -56,176 Closed
TF
134
TIAA FSB
Florida
– -$642K -45,200 Closed
VF
135
Virtu Financial
New York
– -$520K -36,592 Closed
SSA
136
Schonfeld Strategic Advisors
New York
– -$472K -33,277 Closed
EMG
137
Ellington Management Group
Connecticut
– -$307K -21,600 Closed
FRM
138
Fox Run Management
Connecticut
– -$238K -16,738 Closed
CSS
139
Cubist Systematic Strategies
Connecticut
– -$176K -12,376 Closed
Creative Planning
140
Creative Planning
Kansas
– -$150K -10,561 Closed
QT
141
Quantbot Technologies
New York
– -$54K -3,822 Closed
CG
142
Cutler Group
California
– -$35.8K -2,600 -98%
TDC
143
Thompson Davis & Co
Virginia
– -$21K -1,500 Closed
SWP
144
Stratos Wealth Partners
Ohio
– -$9K -630 Closed
KF
145
Krilogy Financial
Missouri
– -$7K -500 Closed
PMFA
146
Plante Moran Financial Advisors
Michigan
– -$1K -77 Closed
2 3 4 5
6

TGTX Hedge Fund Activity: Q2 2018 in Review

132 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2018, worth a combined $534M — down 2.5% from $548M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new TGTX positions and 16 closed out — a net gain of 7 holders — while 50 added to existing stakes and 36 trimmed.

The largest buyer was RA Capital Management, adding an estimated $24.8M. The largest seller was Fidelity Investments, cutting an estimated $16M.

  • 132 institutional investors held TG Therapeutics (TGTX) as of Q2 2018, up from 125 in Q1 2018.
  • Funds reported $534M of TG Therapeutics stock for Q2 2018, down 2.5% quarter-over-quarter.
  • 23 funds opened new TG Therapeutics positions in Q2 2018 and 16 closed out, a net change of +7 holders.
  • The largest TG Therapeutics buyer in Q2 2018 was RA Capital Management, an estimated $24.8M added.
  • The largest TG Therapeutics seller in Q2 2018 was Fidelity Investments, an estimated $16M sold.

Based on aggregated 13F filings for Q2 2018.